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Coronary stenosisAbstract Background: The newer generation of Bioresorbable Vascular Scaffold ABSORB (BVS
1.1) showed better outcome in regard to scaffold area reduction as a result of improved scaffold
design and enhanced polymer processing.
Objective: To assess the safety and efﬁcacy of treating signiﬁcant native coronary artery stenosis
using ABSORB BVS.
Methods: Ninety-nine patients with de novo native signiﬁcant coronary artery stenosis were selected
between September 2012 and September 2014 and were treated using ABSORB BVS. For each
patient, the target and the peri-scaffold segments (5 mm proximal and distal to the scaffold edge)
were analyzed by Quantitative Coronary Angiography (QCA) and Intravascular Ultrasound (IVUS)
immediately after the procedure and at one year of follow-up. The major clinical endpoint was
ischemia-driven major adverse cardiac events (ID-MACE) deﬁned as a composite of cardiac death,
myocardial infarction or ischemia-driven target lesion revascularization (ID-TLR).
Results: At one year, the overall scaffold area did not demonstrate any signiﬁcant change. The
angiographic insegment late lumen loss was estimated to be 0.11 ± 0.19 mm, while the IVUS assess-
ment revealed a non-signiﬁcant decrease in the minimal lumen area by 0.5% (p= 0.79), without sig-
niﬁcant change in the mean lumen area. There were no reported cardiac deaths. However, two cases
of ID-TLR were recorded, one case with STEMI after two weeks due to thrombosis at the distal edge
of the BVS and another case with restenosis after one year. Both were treated with metallic drug-
254 H. Khamis et al.eluting stents (Xience V). At one year the overall ID-MACE was found to be 2%.
Conclusion: The performance of ABSORB BVS in the treatment of signiﬁcant de novo native coro-
nary artery stenosis makes it an attractive option with favorable early and late outcome.
 2016 Egyptian Society of Cardiology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Percutaneous coronary intervention (PCI) with bioresorbable
stents has created interest because the need for mechanical sup-
port for the healing artery is temporary, and after the ﬁrst few
months there are potential disadvantages of a permanent
metallic platform. Stents improve immediate outcomes, includ-
ing profound reduction in acute vessel occlusion after PCI by
supporting intimal tissue ﬂaps separated from deeper layers
and by optimizing vessel caliber. Besides, they limit restenosis
by preventing negative remodeling.1
Restenosis, resulting primarily from intimal hyperplasia
that occurs as a healing response to PCI especially after bare
metal stenting, can be limited by coating stents with antiprolif-
erative medications.2,3
Drug-eluting stents (DES) have greatly improved outcomes
of percutaneous coronary intervention (PCI) by impeding
excessive neointimal proliferation. However, the permanent
presence of the metallic prosthesis and the durable polymer
might impair the natural healing process of the coronary vessel
wall and result in a prolonged inﬂammatory response and sub-
sequent unfavorable clinical outcomes.4,5
Recently, PCI with bioresorbable vascular scaffolds (BVS)
has emerged as an interesting alternative since the presence
of the prosthesis (the scaffold as well as the polymer with the
drug) in the coronary artery is temporary. Moreover, this
novel technology enables to restore the normal vessel reactivity
and facilitates positive remodeling. As a consequence, it
reduces the trigger for persistent inﬂammation and enables fur-
ther interventions both percutaneously and surgically.6
The polymeric material as an implantation medium poten-
tially has numerous advantages compared to metal except for
limited distensibility. Although the radial strength of the
ABSORB (BVS) has been reported to be comparable to metal-
lic stents, this provided the BVS is deployed within the limits of
its size. If the BVS is over-stretched beyond its designed limits,
it has been shown to lose some of its radial strength and may
possibly fracture.7
The six-month results of 30 patients who received ABSORB
everolimus-eluting bioresorbable scaffold were reported in
2008 by Ormiston et al.; the extent of neointima was compara-
ble to that was observed with a metallic everolimus-eluting
stent, but intravascular ultrasound (IVUS) and optical coher-
ence tomography (OCT) demonstrated an angiographic late
loss of 0.44 mm.7 However, at 2-year follow-up, thereby there
was full resorption of the polymeric struts, with return of
vasomotion in the scaffolded area, late luminal enlargement,
thinning of the vessel wall and the absence of constrictive or
expansive remodeling.8
The ﬁrst Egyptian report of using the ABSORB BVS was
described in 2013 by Khamis et al. and included only 30
patients. The current study can be considered a continued
access registry that provides further assessment of the outcomeof this novel technology in a larger cohort of Egyptian patients
and for a longer period of follow-up.9
2. Aim of the work
The aim of this study was the evaluation of the performance of
the Bioresorbable Vascular Scaffold (BVS) for the treatment of
de novo native coronary artery stenosis.
3. Methods
3.1. Study design and study population
It was a prospective, single arm, open label study that included
99 cases admitted to the catheterization laboratory in Wadi El-
Neel hospital between September 2012 and September 2014
and diagnosed as having ischemic heart disease with signiﬁcant
coronary artery stenosis necessitating PCI. We included full
history, clinical evaluation, Standard 12-leads surface ECG,
Echocardiography, ischemia driven non-invasive testing for
controversy patients with chest pain.
The inclusion criteria included stable coronary artery dis-
ease, age P18 and 665 years, and de novo coronary lesions
(excluding left main stem and arterial or saphenous vein
grafts). Main exclusion criteria included acute coronary syn-
drome, the inability to take the dual antiplatelet therapy for
12 months, the left ventricular ejection fraction 630%, and
the lack of the consent for personal data processing and
follow-up. For more details, you can refer to our ﬁrst report
previously published.9
3.2. Study device
3.2.1. Device description
In this study, we used the Absorb BVS (Abbott Vascular,
Santa Clara, CA, USA) which is a fully bioresorbable scaffold
with a backbone composed of poly L-lactide acid (PLLA), cov-
ered by an amorphous matrix, a 1:1 mixture of everolimus and
another polymer, poly-DL-lactide (PDLLA). The scaffold has a
corrugated ring design and is mounted on a Xience delivery
catheter. The scaffold itself is radio-transparent; hence, two
platinum markers are placed near its ends to allow proper
positioning. Since the resorption process occurs mainly due
to hydrolysis resulting in CO2 and H2O as end products and
progresses gradually; minimal or no inﬂammation can be
observed.10
The scaffold is covered with everolimus, a potent antiprolif-
erative drug, which is released at the same rate and amount as
from metallic Xience V stent. The Absorb BVS is a thick-strut
scaffold with an average strut thickness of 157 lm. Currently
three diameters (2.5, 3.0, 3.5 mm), and ﬁve lengths (8, 12, 18,
23, 28 mm) are available.10
Treatment of native coronary artery stenosis 2553.2.2. Scaffold implantation technique
Due to a different structure and mechanical properties of the
BVS as compared with metallic stents, some technical issues
regarding implantation technique need to be discussed. The
polymeric nature of the scaffold carries physical limitations
that should be taken into account before deployment. Due
to strict dilatation limits, overexpansion can lead to strut frac-
ture or disruption of the scaffold inside the vessel. Careful ves-
sel sizing before BVS implantation is crucial for procedural
success.
Generally, the BVS should not be implanted into lesions
that cannot be adequately prepared with balloon inﬂations,
particularly when the pre-dilatation balloon cannot be fully
expanded or when the result of preparation is unsatisfactory.
The deployment should proceed gradually, with pressure incre-
ment by 2 atm every 5 s till complete expansion of the scaffold,
and then target pressure should be maintained for at least 30 s.
Post-dilatation with larger balloons is possible, as long as over-
expansion does not exceed 0.5 mm, as compared with the scaf-
fold nominal diameter. Ultimately, one should aim to obtain
<10% residual stenosis, full scaffold expansion and optimal
strut apposition.3.3. Study procedure
Target lesions were treated using standard techniques with
mandatory pre-dilatation. Post-dilatation was allowed with a
balloon shorter than the implanted stent. Immediate post-
procedural assessment was done using QCA analysis and
IVUS imaging. Bailout stenting with Xience-V for edge dissec-
tion and insufﬁcient coverage of the lesion was recommended
if needed. All patients received aspirin and clopidogrel as
guidelines for DES.3.4. Follow-up
The assessment of the clinical status, detection of adverse
events, details of any subsequent coronary interventions, and
the use and changes in concomitant medications were collected
via regular visits every 3 months. Control angiography with
QCA and IVUS assessment of the target segment was done
at one year.
3.5. Endpoints
The primary endpoint was the cumulative rate of major
adverse cardiovascular events (MACE) including cardiac
death, myocardial infarction (MI) and Ischemia-driven target
lesion revascularization (TLR). Secondary endpoints included
cardiac death, all-cause death, MI, TLR, target vessel revascu-
larization (TVR), stent thrombosis (ST), and device success
rate. Cardiac death included death resulting from an acute
MI, sudden cardiac death, death due to heart failure and death
due to cardiac procedures. All deaths were deemed cardiac
unless proven otherwise.
MI was deﬁned according to the third universal deﬁni-
tion.11 Clinically-driven TLR was deﬁned as the need for sub-
sequent intervention of the target lesion due to the presence of
a symptomatic P50% diameter stenosis during follow-up.TVR was deﬁned as any revascularization of any segment of
the index coronary artery. The device success was deﬁned as
successful deployment of the BVS in the target site without sys-
tem failure.3.6. Definitions
 Minimal Luminal Diameter (MLD) = The smallest lumen
diameter in the segment of interest.
 Reference Vessel Diameter (RVD) = The averaged diame-
ter of the coronary artery assumed without atherosclerotic
disease.
 Acute gain = Post-procedural MLD – pre-procedural
MLD.
 Late loss (LL) = Post-procedural MLD – MLD at follow-
up.
 Diameter stenosis (DS) = (RVD-MLD)/RVD.
 Binary restenosis (BR) = DS > 50% at follow-up coro-
nary angiography in the treated coronary segment.12
3.7. Statistical analysis
The clinical data were recorded on a report form. These data
were tabulated and analyzed using the computer program
SPSS (Statistical package for social science) version 16 to
obtain the following:
 Descriptive data
Descriptive statistics were calculated for the data in the
form of the following:
– Mean and standard deviation for quantitative data.
– Frequency and distribution for qualitative data.
 Analytical statistics
In the statistical comparison between the different values,
the signiﬁcance of difference was tested using Paired t-test,
and used to compare means of quantitative data. A P value <
0.05 was considered statistically signiﬁcant while P value <
0.01 was considered highly signiﬁcant in all analyses. For
binary variables, percentages were calculated. When provided,
the 95% conﬁdence intervals were computed with the
Gaussian approximation, taking into account the paired
analysis. Paired comparisons between post procedural and
follow-up results were done by a Wilcoxon signed-rank test.134. Results
4.1. Baseline clinical and angiographic characteristics
Ninety-nine patients were enrolled in the study. The mean age
of the study population was 57.7 ± 9.5 years and about 60%
were males. The initial angiographic evaluation revealed that
the majority of target lesions were of type A and the target ves-
sel was predominantly the LAD. The detailed characteristics
are described in Table 1.
Table 1 Baseline clinical and angiographic data (n= 99).
Age, mean ± SD, y 57.75 ± 9.55
Male gender, n (%) 60(60.6%)
Current smoker, n (%) 38(38.4%)
Diabetes mellitus, n (%) 40(40.4%)
Hypertension requiring medication, n (%) 69(69.7%)
Hyperlipidemia requiring medication, n (%) 47(47.5%)
Prior myocardial infarction, n (%) 26(26.2%)
SYNTAX score (mean ± SD) 7.77 ± 3.77
Target vessel, n (%)
Left anterior descending artery 46(46.4%)
Left circumﬂex 21(21.2%)
Right coronary artery 32(32.3%)
AHA/ACC lesion classiﬁcation, n (%)
A 62(62.6%)
B1 25(25.3%)
B2 9(9.1%)
C 3(3.0%)
Mean reference vessel diameter, mean ± SD,
mm
2.82 ± 0.53
MLD (Minimum Luminal Diameter), mean
± SD, mm
0.93 ± 0.26
DS(Diameter Stenosis), mean ± SD, % 66.49 ± 9.34%
Lesion length, mean ± SD, mm 10.47 ± 4.64
256 H. Khamis et al.The BVS was implanted in all patients successfully and no
bailout stents were required. There were no documented car-
diac or non-cardiac deaths, either peri-procedurally or at one
year. After two weeks, one patient presented with inferior
STEMI, and control coronary angiography revealed a patent
BVS in the mid LCX with a thrombus at its distal end that
was treated with a metallic drug-eluting stent (Xience V).
Another patient started to complain from stable angina class
II after 12 months of BVS implantation and his angiography
revealed signiﬁcant target lesion restenosis in the LAD which
necessitated implanting a Xience V stent. Hence, the calculated
ID-MACE after one year of follow-up was found to be 2%.
All patients completed 12 months of dual antiplatelet therapy
of aspirin and clopidogrel without interruption.Table 2 Paired QCA Analysis (n= 98).
Parameter Segment
Proximal
RVD, mean ± SD, mm
After the procedure 3.05 ± 0.49
At 1 year follow-up 2.93 ± 0.49
P value <0.001
MLD, mean ± SD, mm
After the procedure 2.74 ± 0.47
At 1 year follow-up 2.63 ± 0.50
P value <0.001
Immediate gain, mean ± SD, mm –
Late loss, mean ± SD, mm 0.11 ± 0.21
DS, mean ± SD, %
After the procedure 10.33 ± 2.60
At 1 year follow-up 10.03 ± 7.0
P value 0.6354.2. Angiographic results
Although ninety-nine patients were initially enrolled, one
patient required a metallic stent due to STEMI in the target
vessel. Therefore, he was excluded from the angiographic
assessment at one year. Table 2 summarizes the results of
QCA data analysis at baseline and at one year of follow-up.
The intrascaffold MLD decreased from 2.60 ± 0.46 to
2.33 ± 0.48 mm (P< 0.001) with signiﬁcant changes in
MLD at the proximal and distal edges of the scaffold as well.
The angiographic late loss inside the scaffold was estimated to
be 0.27 ± 0.20 mm and the in-scaffold binary restenosis was
0%, whereas one proximal edge restenosis was documented
by angiography in a symptomatic patient (1 of 98; 1.02% in-
segment binary restenosis) (see Fig. 1).
4.3. IVUS assessment results
In the present study, the target segments in ninety-eight
patients were evaluated using IVUS immediately following
the procedure and after one year. The results of this evaluation
are summarized in Table 3. Over one year, there was a non-
signiﬁcant increase in the vessel area, while slight decreases
in the minimum scaffold area, mean lumen area, and minimum
lumen area were reported and considered insigniﬁcant as
demonstrated in Fig. 2.
5. Discussion
Despite the advances in design and technology of drug-eluting
stents (DES) and improved long-term outcome, the implanta-
tion of bioresorbable vascular scaffold (BVS) has potential
advantages including maintaining the physiological vasomo-
tion and allowing for easier non-invasive assessment and sub-
sequent graft anastomosis if needed as a result of absent long-
term metallic platform. Therefore, the BVS may become a very
promising alternative to DES. Consequently, our principle
interest in this study was to evaluate the performance of
BVS as an alternative to metallic stents with particular focus
on thrombosis and restenosis at one year (see Fig. 3).In-Scaﬀold Distal In-Segment
2.95 ± 0.50 2.83 ± 0.50 2.91 ± 0.50
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<0.001 <0.001 <0.001
2.60 ± 0.46 2.52 ± 0.47 2.38 ± 0.45
2.33 ± 0.48 2.41 ± 0.49 2.27 ± 0.47
<0.001 <0.001 <0.001
1.67 ± 0.46 – –
0.27 ± 0.20 0.11 ± 0.18 0.11 ± 0.19
12.02 ± 3.07 11.0 ± 3.10 18.23 ± 3.26
18.55 ± 6.89 11.67 ± 6.8 17.85 ± 6.87
<0.001 0.275 0.538
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Figure 1 QCA analysis at baseline and at one year.
Table 3 IVUS Results, Paired Gray-Scale IVUS Measurements per Lesion, (n= 98).
Parameter Post PCI (Mean ± SD) At 1 year (Mean ± SD) Diﬀerence (95% CI)
based on individual data, %
P
Vessel area, mm2 13.86 ± 1.97 14.25 ± 1.9 (0.155 to 0.935) 0.16
Scaﬀold area, mm2 6.45 ± 0.89 6.45 ± 0.90 (0.09) to (0.09) 0.985
Minimum scaﬀold area, mm2 5.48 ± 0.75 5.47 ± 0.75 (0.20 to 0.22) 0.92
Mean lumen area, mm2 6.45 ± 0.90 6.42 ± 0.96 (0.04) to (0.11) 0.393
Minimum lumen area, mm2 5.48 ± 0.75 5.45 ± 0.82 (0.25) to (0.19) 0.79
Lumen area stenosis, % 12.34 ± 2.76 12.99 ± 2.82 (0.136 to 1.436) 0.104
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Figure 2 Comparison of IVUS results at baseline and after one year.
Treatment of native coronary artery stenosis 257According to our results, we reported that the insegment
late luminal loss at one year of BVS was estimated at 0.11 ±
0.19 mm by QCA calculation. However, this value is quite sim-
ilar to that observed after the same period of stenting using
everolimus eluting metallic stents (0.12 mm) in some reg-
istries.14 This value is expected to decrease over time particu-
larly after complete disappearance of the BVS strutsanticipated at two years. This assumption is based on the ini-
tial data from our ﬁrst report of evaluating BVS in Egyptian
patients, as the calculated insegment late luminal loss was
0.27 ± 0.32 mm at 6 months. This showed signiﬁcant reduc-
tion after 12 months (p= 0.001).9
This can be attributed to the novel design of the second
generation BVS 1.1 with stronger platform to reduce recoil
(a) (b) (c) (d)
(e) (f)
(g) (h) (i)
(j)
Figure 3 (a) Mid-LAD lesion. (b) IVUS assessment. (c) Balloon dilatation for lesion preparation. (d) BVS deployment. (e) Angiographic
result. (f) IVUS assessment (post-procedural). (g) Angiography at 12 months. (h) Zoom into show radiopaque dots. (i) QCA assessment at
12 months. (j) IVUS assessment at 12 months.
258 H. Khamis et al.and limit negative remodeling, and more controlled eluting
process which possibly reduces neointimal proliferation. In
addition, it should be noted that we expressed our IVUS
assessment values in terms of area sections rather than vol-
umes because IVUS measurement of the length is not reliable
as the mechanical pullback can be hindered by tortuosity or
calcium deposits.
Noteworthy, ID-MACE in our cohort was found to be 2%
at 12 months which is considered favorable in comparison withthe results reported with metallic stents in previous studies.14
One case of stent thrombosis was reported at two weeks after
the index procedure which necessitated stenting using a metal-
lic stent (1/99). The patient presented with STEMI and a
thrombus was observed at the distal edge of the BVS upon
angiography. The actual reason and mechanism of this event
could not be conﬁrmed, as the patient was compliant on his
medications including dual antiplatelet therapy. The patient
continued on the same antiplatelet drugs after a metallic stent
Treatment of native coronary artery stenosis 259with similar polymer and eluted drug, and his follow-up was
free of any MACE which might rule out clopidogrel resistance
or polymer hypersensitivity. On the other hand, the possibility
of strut fracture or malposition is more likely to be accepted;
however, this could not be conﬁrmed as IVUS and OCT
assessment was not feasible in the emergency presentation
and was excluded for patient’s safety.
Furthermore, the angiographic assessment revealed a statis-
tically signiﬁcant difference in the RVD and MLD at baseline
and after 12 months; however, there was non-signiﬁcant inseg-
ment diameter stenosis (DS) with a p value of 0.5 and binary
restenosis detected in only one patient (1/98, 1.02%). The
IVUS data conﬁrmed these results and showed non-
signiﬁcant changes in the mean scaffold area, minimal scaffold
area, mean lumen area and minimal lumen area.
Data from a new study (ABSORB Japan) are coherent with
our results. For patients who received the Absorb stent, the
primary endpoint of target lesion failure at 12 months was
4.2%. The angiographic measurement of the insegment late
lumen loss was 0.13 mm with the Absorb stent. The twelve-
month clinical outcomes showed no difference in the rate of
cardiac death, target vessel MI, or ischemia driven target lesion
revascularization between the two treatment groups (the BVS
and metallic stent arms) and the rate of stent thrombosis at
12 months was 1.5% in both stent arms.14
Other registries have reported a fairly high incidence of
stent thrombosis in patients with bioresorbable stents. The
occurrence of stent thrombosis particularly in the subacute
phase suggests that the risk is associated with factors related
to the scaffold, the lesion, implantation technique, or a combi-
nation of these factors (calcium, adequate predilatation,
expansion, apposition, etc).15
The favorable results of our study can be argued to be a
result of the careful selection of the cases and the relatively
non-complex lesions. However, this can be considered a ﬁrst
Egyptian report of BVS assessment at 12 months and further
studies might include more complex lesions such as bifurca-
tions or CTO, and higher risk patients as acute coronary syn-
drome scenarios. Consequently, this may raise a question
about whether the use of metal stents might wane in the future
and be replaced by this novel technology.
6. Conclusion
Based on the favorable outcome of the BVS use in treating
native de novo coronary artery stenosis documented in this
study, we can claim that BVS is a notable option for this
patient subset with reasonable performance, promising results
and paramount clinical advantage.
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